Gadolinium Deposition Disease

Gadolinium, a heavy metal used in MRI contrast agent dyes, may cause a serious illness – Gadolinium Deposition Disease – if it is retained in the body following a scan.

Symptoms of Gadolinium Deposition Disease Following an MRI? Contact an Attorney Today.

The nationwide law firm of Bernstein Liebhard LLP is offering free, no-obligation legal reviews to individuals who may be experiencing symptoms allegedly associated with Gadolinium Deposition Disease following an MRI. To discuss your case with one of our attorneys today, please call (888) 994-5118.

Symptoms of Gadolinium Contrast Disease

There are currently 8 gadolinium-based contrast agents approved for use in the United States:

  • Dotarem
  • Eovist
  • Gadavist
  • Magnevist
  • MultiHance
  • Ominiscan
  • OptiMARK
  • ProHance

These products have long been considered safe for patients with normal kidney function. However, several recent studies suggest that gadolinium deposits can remain in the brain and other parts of the body long after a patient has undergone an MRI.

Plaintiffs in a growing number of MRI contrast dye lawsuits claim that gadolinium toxicity from these deposits can result in a debilitating condition called Gadolinium Deposition Disease.

Symptoms of the disorder include at least 3 of the following:

  • Cognitive impairment, “brain fog”, memory problems
  • Headaches
  • Bone and joint pain
  • Spongy or rubbery skin
  • Thickened and painful ligaments
  • Tightness in the hands and feet

Additional gadolinium side effects may include gastrointestinal issues, such as diarrhea and abdominal pain, as well as abnormal heart rhythms and other cardiac problems.

FDA Warning for Gadolinium Retention

In December 2017, the FDA issued a class warning for gadolinium contrast dyes because of the risk that gadolinium could be retained in the brain or other parts of the body for weeks, months, and even years after a patient has undergone an MRI.

“To date, the only known adverse health effect related to gadolinium retention is a rare condition called nephrogenic systemic fibrosis (NSF) that occurs in a small subgroup of patients with pre-existing kidney failure,” the agency said. “We have also received reports of adverse events involving multiple organ systems in patients with normal kidney function. A causal association between these adverse events and gadolinium retention could not be established.”

While the warning applied to all 8 gadolinium-based MRI contrast dyes currently approved for sale in the United States, the FDA noted that certain products called linear agents — Eovist, Magnevist, Multihance, Omniscan, and OptimMARK — resulted in more retention and retention for a longer time compared to other agents.

The FDA is advising health care providers to consider the retention characteristics of each agent when choosing a gadolinium product for patients who may be at higher risk for retention, including:

  • Patients requiring multiple lifetime doses
  • Pregnant women
  • Children
  • Patients with inflammatory conditions

Learn More About Filing a Lawsuit for Gadolinium Deposition Disease

You may be entitled to compensation for medical bills and other damages if you or someone you love developed symptoms of Gadolinium Deposition Disease following an MRI. To arrange for your free, no-obligation case review, please call (888) 994-5118.

  1. FDA (December 2018) “FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings”
  2. Richard Semelka, MD Consulting (April 2018) “Gadolinium in Humans Revisited: Emphasis on Gadolinium Deposition Disease – Part 1”
  3. Richard Semelka, MD Consulting (May 2018) “Gadolinium in Humans Revisited: Emphasis on Gadolinium Deposition Disease – Part 2”
Last Modified: June 11, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content